Amzak Health Investors

Sound Blade Medical is an early stage medical device startup that revolutionizes healthcare by enhancing endoscopic, image-guided histotripsy.

ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, founded in 2016. The company specializes in developing bio-engineered surgical implants aimed at facilitating new tissue growth and aiding in connective tissue repair. Its primary product, the Bridge-Enhanced ACL Repair technology, offers a viable alternative to traditional anterior cruciate ligament (ACL) reconstruction for patients who have suffered ACL injuries. This innovative approach enables surgeons to restore the normal anatomy and function of the knee, enhancing recovery outcomes for patients.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapies for Long QT Syndrome and various arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, atrial fibrillation, and treatment-resistant cancers. Thryv Therapeutics is dedicated to creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to reduce the risk of sudden cardiac death and enhance the quality of life for affected patients. Through its targeted therapeutic development, the company seeks to provide effective solutions for serious cardiovascular and oncological conditions.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, founded in 2016. The company specializes in developing bio-engineered surgical implants aimed at facilitating new tissue growth and aiding in connective tissue repair. Its primary product, the Bridge-Enhanced ACL Repair technology, offers a viable alternative to traditional anterior cruciate ligament (ACL) reconstruction for patients who have suffered ACL injuries. This innovative approach enables surgeons to restore the normal anatomy and function of the knee, enhancing recovery outcomes for patients.

MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, concentrating on the clinical development of innovative cancer therapies. The company's pipeline includes Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently undergoing Phase II trials for relapsed or refractory follicular lymphoma and Phase Ib trials for B-cell malignancies. Another key candidate is Voruciclib, an oral cyclin-dependent kinase inhibitor in Phase Ib trials for acute myeloid leukemia and B-cell malignancies. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, currently in Phase I trials. Pracinostat, an oral histone deacetylase inhibitor, is also in Phase II trials aimed at treating myelodysplastic syndrome. The company has established strategic collaborations and licensing agreements with various organizations to enhance its research and development efforts. Founded in 2000, MEI Pharma was previously known as Marshall Edwards, Inc. and rebranded in 2012.

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in San Francisco, California, that specializes in developing treatments for diseases related to transthyretin (TTR) amyloidosis. The company is advancing AG10, an orally administered small molecule currently in phase 3 clinical trials, which aims to stabilize tetrameric TTR and interrupt the molecular processes leading to amyloidosis. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, which focuses on creating genetically targeted therapies designed to address the underlying causes of various diseases. Through its innovative approach, Eidos Therapeutics seeks to provide potentially disease-modifying therapies to meet the significant medical needs associated with TTR-related conditions.

GTx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for stress urinary incontinence and prostate cancer. The company specializes in selective androgen receptor modulators (SARMs) and selective androgen receptor degraders, targeting conditions such as breast cancer and Duchenne muscular dystrophy. One of its notable product candidates is enobosarm GTx-024, which is undergoing Phase II clinical trials for patients with specific types of breast cancer and postmenopausal women suffering from stress urinary incontinence. Founded in 1997 and based in Memphis, Tennessee, GTx aims to advance medical solutions by leveraging new scientific approaches. In 2019, GTx was acquired by Oncternal Therapeutics in a reverse merger.

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for obstructive sleep apnea (OSA). The company has created the Inspire system, a neurostimulation technology designed to provide safe and effective treatment for moderate to severe OSA. This system employs a proprietary Upper Airway Stimulation (UAS) therapy that utilizes established technologies from cardiac pacing and neurostimulation. Additionally, Inspire is developing a novel closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to keep the airway open. Founded in 2007 and headquartered in Golden Valley, Minnesota, Inspire primarily generates its revenue in the United States, with a growing presence in Europe.

Essential Medical, Inc. has developed two femoral artery closure devices intended to seal femoral punctures following vascular access medical procedures requiring a cardiac catheterization. MANTA is designed to close large bore punctures (10-24F) following procedures such as transcatheter aortic valve replacement (TAVR), abdominal aortic aneurysm repair (AAA/PVAR), and balloon aortic valvuloplasty (BAV). These procedures are one of the fastest growing segments within interventional cardiology.

KEW Group is a personalized oncology management company based in Cambridge, Massachusetts, founded in 2009. It specializes in DNA-based genomic testing and interpretation services, aiming to enhance cancer care through individualized treatment options. By leveraging proprietary oncology therapeutic pathways and personalized medicine tools, KEW Group utilizes genetic and genomic information to inform clinical decision-making in community oncology settings. The company's focus is on identifying genetic variants in solid tumors and matching them with targeted therapies, thereby improving treatment decisions and the overall quality of patient care. KEW Group is committed to advancing oncology precision medicine and expanding the capabilities of molecular labs in the field.

Marbles: The Brain Store, a specialty retailer with a collection of games, puzzles, books and software designed to strengthen the brain